Abstract Number: 1300 • ACR Convergence 2020
Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach
Background/Purpose: Cognitive impairment (CI) is usually operationalized on the American College of Rheumatology Neuropsychological Battery (ACR-NB) as a z-score of ≤-1.5 on ≥2 domains or…Abstract Number: 1688 • ACR Convergence 2020
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome…Abstract Number: 1788 • ACR Convergence 2020
Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE
Background/Purpose: Cognitive impairment (CI) is among the earliest and the most prevalent manifestations of SLE. Previous studies have demonstrated that the increased levels of interferon…Abstract Number: 1804 • ACR Convergence 2020
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Background/Purpose: Tryptophan (TRP) is metabolized to kynurenine (KYN), quinolonic acid [QA, a N-methyl D-aspartate receptor (NMDAR) agonist] and kynurenic acid (KA, an NMDAR antagonist). KYN/TRP…Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…Abstract Number: 1819 • ACR Convergence 2020
Altered Brain Functional Connectivity in Systemic Lupus Erythematosus
Background/Purpose: Cognitive dysfunction (CD) is very prevalent in SLE and significantly affects quality of life. Altered functional brain mechanisms are associated with CD in SLE.…Abstract Number: 0026 • ACR Convergence 2020
A Modified Version of the 2016 ACR Fibromyalgia Criteria Cognitive Items Results in Stronger Correlation Between Subjective and Objective Measures of Cognitive Impairment
Background/Purpose: In a previous study, we showed that the subjective item assessing cognitive impairment (SSS-Cog) for fibromyalgia (FM) did not correlate with objective cognitive measures.…Abstract Number: 0488 • ACR Convergence 2020
Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…Abstract Number: 1260 • ACR Convergence 2020
Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus
Background/Purpose: There is a consistent relationship between cognition and depression and anxiety (affective symptoms) in lupus. Together, affective and cognitive symptoms represent among lupus’ most…Abstract Number: 1268 • ACR Convergence 2020
Structural Validity of a Comprehensive Neuropsychological Battery for Assessment of Cognitive Impairment in Systemic Lupus Erythematosus: Exploratory Factor Analysis Confirms Six Cognitive Domains
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to neuropsychiatric manifestations including cognitive impairment (CI). The gold standard for assessment of SLE cognitive function is the…Abstract Number: 1276 • ACR Convergence 2020
Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
Background/Purpose: Cognitive impairment (CI) is common in systemic lupus erythematosus (SLE) patients, however there is no standard screening tool available. The American College of Rheumatology…Abstract Number: 122 • 2020 Pediatric Rheumatology Symposium
Systemic Inflammation and Cognitive Dysfunction in jSLE Patients
Background/Purpose: Neurocognitive dysfunction (NCD) is one of the most commonly reported neuropsychiatric symptoms in patients with juvenile systemic lupus erythematosus (SLE), even without overt CNS…Abstract Number: 677 • 2019 ACR/ARP Annual Meeting
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
Background/Purpose: Cognitive impairment (CI) is a common neuropsychological manifestation of Systemic Lupus Erythematosus (SLE) with a prevalence of 38% [95% confidence interval: 33,43%]. Previous studies,…Abstract Number: 1612 • 2019 ACR/ARP Annual Meeting
Disease Activity and Cognitive Function in Systemic Lupus Erythematosus
Background/Purpose: Cognitive dysfunction (CD) is a common symptom in systemic lupus erythematosus (SLE), that significantly affects quality of life but there are limited treatment options…Abstract Number: 1792 • 2019 ACR/ARP Annual Meeting
Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)
Background/Purpose: Cognition dysfunction (CD) is a poorly understood non-stroke central neurologic manifestation of antiphospholipid syndrome, whose diagnosis involves a specific neuropsychological (NP) evaluation. Brain-derived neurotrophic…
- 1
- 2
- 3
- 4
- Next Page »